This information is being shared with you to ensure you understand the risks and benefits of receiving the AstraZeneca/COVIDSHIELD vaccine. The AstraZeneca/COVIDSHIELD vaccine is:

• Approved and recommended for use by Health Canada for adults aged 18 and over.
• Currently being used in 110 countries.
• Has been administered to more than 700,000 Canadians.
• Has been administered to more than 20,000 individuals in Newfoundland and Labrador.
• 82% effective in preventing serious illness and hospitalization from COVID-19 infection (about two weeks after your second dose).

Of note there is a:

• 1 in 5 risk of blood clots from COVID-19 infection.
• 1 in 100,000 risk of blood clots from receiving the AstraZeneca/COVIDSHIELD vaccine.
• Known and effective treatment for blood clots linked to the AstraZeneca/COVISHIELD vaccine.

An mRNA vaccine is now preferred as the second dose for individuals who received a first dose of AstraZeneca/COVISHIELD. This is based on emerging evidence of better immune response from this mixed vaccine schedule, and to mitigate the potential risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) associated with viral-vector vaccines.

Currently, mRNA and AstraZeneca/COVISHIELD vaccine are both available in Newfoundland and Labrador. Therefore, those who wish to have a second dose with mRNA will not be delayed in receiving that vaccine.  If a person chooses an mRNA vaccine for their second dose, they do not need to restart a series.

If you still have questions after reviewing this information, please contact your health care provider prior to booking an appointment.